Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Amol Kumar Narang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0876-4967; OpenAlex author ID A5029871629, A5136823037. Sources: ClinicalTrials.gov.

Their work

Papers
74 (first author 2, last author 18)
Trials
4 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
262
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 7 papers, 1 trial · 2019: 6 papers, 1 trial · 2020: 1 paper · 2021: 8 papers, 1 trial · 2022: 20 papers · 2023: 4 papers · 2024: 6 papers · 2025: 6 papers · 2026: 8 papers

Papers 50 of 74

  1. Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-026-01600-0↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  4. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  5. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  6. Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity. Last author DOI 10.1016/j.ijrobp.2022.07.1120↗
  7. Nourishing Hope: Five Essential Nutrition Tips for Patients With Pancreatic Cancer. Co-author DOI 10.6004/jadpro.2026.17.2.2↗
  8. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  9. Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study. Last author DOI 10.1007/s00520-025-09339-3↗
  10. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. First author DOI 10.1016/j.ijrobp.2024.10.026↗
  11. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  12. Optimal Target Volume Delineation for Pancreatic Cancer: Triangulating What Should be Targeted. Co-author DOI 10.1016/j.semradonc.2025.08.003↗
  13. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  14. Leveraging the Immune Response from LIFE Biomaterial and Photon-Flash in Pre-Clinical Pancreatic Cancer Treatment. Co-author DOI 10.3390/pharmaceutics17101273↗
  15. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… Co-author DOI 10.1016/j.prro.2023.11.011↗
  16. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  17. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  18. Consensus, debate, and prospective on pancreatic cancer treatments. Co-author DOI 10.1186/s13045-024-01613-x↗
  19. Variation in outcomes and practice patterns among patients with localized pancreatic cancer: the impact of the pancreatic cancer multidisciplinary clinic. Last author DOI 10.3389/fonc.2024.1427775↗
  20. Characterizing Compromised Target Coverage With Hypofractionated Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.7759/cureus.66882↗
  21. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  22. Effectiveness of the nutrition referral system in a multidisciplinary pancreatic cancer clinic. Last author DOI 10.1007/s00520-023-07795-3↗
  23. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  24. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers15041252↗
  25. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Last author DOI 10.1002/cam4.4527↗
  26. Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Co-author DOI 10.1007/s00261-021-03353-9↗
  27. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  28. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-022-06667-x↗
  29. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  30. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.clon.2021.12.014↗
  31. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Last author DOI 10.1016/j.prro.2022.01.005↗
  32. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  33. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  34. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
  35. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  36. A safety study of intraoperative radiation therapy following stereotactic body radiation therapy and multi-agent chemotherapy in the treatment of localized pan… Last author DOI 10.1186/s13014-022-02145-9↗
  37. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  38. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  39. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  40. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resecta… Last author DOI 10.21037/jgo-21-513↗
  41. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Last author DOI 10.21037/jgo-22-38↗
  42. Finite Element-Based Personalized Simulation of Duodenal Hydrogel Spacer: Spacer Location Dependent Duodenal Sparing and a Decision Support System for Spacer-E… Co-author DOI 10.3389/fonc.2022.833231↗
  43. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Insti… Last author DOI 10.3390/curroncol29010028↗
  44. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Last author DOI 10.3857/roj.2021.01060↗
  45. Geometric Reproducibility of Fiducial Markers and Efficacy of a Patient-Specific Margin Design Using Deep Inspiration Breath Hold for Stereotactic Body Radiati… Last author DOI 10.1016/j.adro.2021.100655↗
  46. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  47. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.11.017↗
  48. Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy? Last author DOI 10.1186/s13014-021-01782-w↗
  49. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Last author DOI 10.1186/s13014-021-01969-1↗
  50. The Feasibility of Haar Feature-Based Endoscopic Ultrasound Probe Tracking for Implanting Hydrogel Spacer in Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.759811↗

Trials 4

  1. Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients Principal investigator NCT04843306↗
  2. Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Principal investigator NCT03767582↗
  3. Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer Principal investigator NCT03307564↗
  4. ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) Study chair NCT00313560↗

Closest collaborators

The 25 strongest of 262 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 44 shared papers, 2012–2026 · strength 5.50
  2. Jin Peng He · 37 shared papers, 2017–2026 · strength 4.77
  3. Lei Zheng · 33 shared papers, 2012–2026 · strength 4.05
  4. Daniel A. Laheru · 29 shared papers, 2012–2026 · strength 3.15
  5. Colin Hill · 18 shared papers, 2021–2026 · strength 2.90
  6. Jeffrey John Meyer · 16 shared papers, 2020–2026 · strength 2.65
  7. Abhinav V. Reddy · 13 shared papers, 2021–2026 · strength 2.16
  8. Shuchi Sehgal · 13 shared papers, 2021–2026 · strength 2.05
  9. Amy Hacker‐Prietz · 16 shared papers, 2017–2025 · strength 2.02
  10. Richard Andrew Burkhart · 15 shared papers, 2019–2026 · strength 1.87
  11. Dung Thi Le · 16 shared papers, 2012–2026 · strength 1.74
  12. Elizabeth M. Jaffee · 11 shared papers, 2012–2026 · strength 1.44
  13. Christopher Lee Wolfgang · 17 shared papers, 2012–2022 · strength 1.41
  14. Ana De Jesus‐Acosta · 11 shared papers, 2017–2026 · strength 1.32
  15. Matthew John Weiss · 14 shared papers, 2017–2022 · strength 1.27
  16. Eun Ji Shin · 12 shared papers, 2017–2024 · strength 1.23
  17. Ralph H. Hruban · 15 shared papers, 2012–2022 · strength 1.20
  18. Elliot K. Fishman · 13 shared papers, 2012–2023 · strength 1.16
  19. Kai Ding · 9 shared papers, 2017–2025 · strength 1.16
  20. Ding Ding · 9 shared papers, 2019–2026 · strength 1.02
  21. Christopher L. Wolfgang · 8 shared papers, 2018–2025 · strength 1.00
  22. Robert A. Anders · 7 shared papers, 2021–2026 · strength 0.96
  23. Lei Zheng · 5 shared papers, 2019–2025 · strength 0.93
  24. William R. Burns · 8 shared papers, 2021–2023 · strength 0.92
  25. Priya Pathak · 3 shared papers, 2024–2026 · strength 0.89

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.